PATENT CLAIM ANALYSIS

Application Number: 16170134
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "234200"]

Abstract:
The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.

Claim (Index 3):
The method of  claim 1 , wherein the type 2 diabetes patient has an estimated glomerular filtration rate (eGFR; mL/minute/1.73 m 2 ) level down to 30.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 97.0
- Lexical Diversity: 1.05556
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15616974', '15918401', '15354053', '14918727', '14928048']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7335460453983632
- 35 USC 102 Novelty (BERT): 0.5685666992467635
- Combined Prediction Score: 0.7170481107832032
- Mean Citation Score: 371.19762
- Max Citation Score: 489.67908
- Similarity Product: 311.91195547041895

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test